The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Exploration of the effect of treatment to progression with the VEGF signaling inhibitor cediranib (CED) plus chemotherapy (CT) on the results of the HORIZON (HZ) II trial in first-line metastatic colorectal cancer.
A. Fielding
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
P. M. Hoff
Consultant or Advisory Role - AstraZeneca
L. Pike
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
D. Wilson
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
J. D. Robertson
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca